In interviews with Targeted Oncology, Ronan J. Kelly, MD, MBA, and David Zhen, MD, discuss the CheckMate 649 trial of nivolumab plus ipilimumab and look back on last year's ODAC meeting on its use in PD-L1–negative gastrointestinal cancers.
Ronan J. Kelly, MD, MBA
Ronan Kelly, MD, MBA, specializes in medical oncology at Texas Oncology-Baylor Charles A. Sammons Cancer Center in Dallas, Texas.
Articles by Ronan J. Kelly, MD, MBA
Ronan J. Kelly, MD, MBA, discusses the targeted therapy options that have become available for patients with gastric, esophageal, and gastroesophageal junction cancers.